Biogen Pharmachem Share Price Today

Biogen Pharmachem Q2FY27 Results: turns profitable at ₹25.73 lakh

Biogen Pharmachem Industries posted a net profit of ₹25.73 lakh in Q2FY27, reversing a net loss of ₹49.15 lakh in Q2FY26. Total income for Q2FY27 was ₹28.33 lakh, entirely from other income; revenue from operations remained nil. Total expenses fell to ₹2.61 lakh in Q2FY27 from ₹38.67 lakh in Q2FY26. H1FY27 net profit stood at ₹47.87 lakh; cash and cash equivalents closed at ₹1.27 lakh as at September 30, 2026. Equity share capital rose to ₹10,530.37 lakh as at September 30, 2026, from ₹9,026.03 lakh as at March 31, 2026.

Rama Shiva Lease Finance exits 4.04% stake in Biogen Pharmachem

Rama Shiva Lease Finance sold all 4.25 crore shares in Biogen Pharmachem Industries. The stake represented 4.04% of the company's total voting capital. The transaction was executed via open market sale on October 16, 2026. Post-transaction holding for the entity is now zero.

Biogen Pharmachem 31st AGM passes all resolutions with strong votes

Biogen Pharmachem Industries held its 31st AGM on September 29, 2026, passing all three ordinary resolutions. Resolution 1 (adoption of FY26 financial statements) received 99.98% votes in favour, with 55315737 votes for and 11649 against. Resolution 2 (reappointment of Kelash Bunkar as director) received 99.64% votes in favour, with 55126620 votes for and 200766 against. Total votes polled stood at 55327386, representing 5.254% of outstanding shares of 1053036833. M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot, was appointed as statutory auditors.

Biogen Pharmachem posts ₹85.95 lakh net profit in FY26, schedules AGM

Biogen Pharmachem posted a net profit of ₹85.95 lakh in FY26, reversing a prior-year loss. Total revenue rose 113.5% to ₹255.80 lakh, driven by interest income and capital gains. The company scheduled its 31st AGM for September 29, 2026, via video conferencing. Paid-up capital increased to ₹90.26 crore following conversion of warrants to equity shares.

Biogen Pharmachem Q1 Results: Net profit rises to ₹22.14 lakh, revenue up YoY

Biogen Pharmachem Industries returned to profitability in Q1FY26 with a net profit of ₹22.14 lakh, reversing a loss in the prior quarter. Revenue stood at ₹44.34 lakh, driven by other operating income, while expenses dropped significantly. Statutory auditors Goenka Mehta And Associates reviewed the results.

Biogen Pharmachem closes trading window for Q1FY27 results

Biogen Pharmachem Industries Ltd has shut its trading window from July 1, 2026, until 48 hours post the announcement of its Q1FY27 unaudited results, adhering to SEBI's insider trading regulations. The board meeting date for the results review is pending announcement.